discontinue sulfonylurea when starting glp-1 receptor agonist Use of continuous glucose monitoring initiating glucagon‐like peptide‐1 therapy in insulin‐treated diabetes - Hirsch - 2024 - Diabetes, Obesity and Metabolism A System-Based Review on Effects

The global GLP-1 Weight Loss Drug Market encompasses glucagon-like peptide-1 receptor agonists, dual GIP/GLP-1 agonists, and emerging triple-receptor agonists approved or in development for chronic weight management, type 2 diabetes remission, and metabolic disease intervention

The review evaluated whether a specific time to pause the use of a GLP-1 or dual GIP/GLP-1 RAs prior to anaesthesia could be recommended

Promoting Gut Health GLP-1 boosts gut health through different actions

1 The incretin effect was termed when researchers noted that individuals had a greater secretion of insulin following an oral glucose challenge as opposed to IV glucose administration

You recently published an editorial about the additional benefits of GLP-1 receptor agonists